Filtered By:
Cancer: Pancreatic Cancer
Drug: Taclonex
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Activation of Vitamin D/VDR Signaling Reverses Gemcitabine Resistance of Pancreatic Cancer Cells Through Inhibition of MUC1 Expression
ConclusionThese findings demonstrate a previously unidentified vitamin D/VDR-MUC1 signaling axis involved in the regulation of gemcitabine resistance in PDA and suggests that combinational therapies that include targeted activation of vitamin D/VDR signaling may improve the outcomes of patients with PDA.
Source: Digestive Diseases and Sciences - April 18, 2023 Category: Gastroenterology Source Type: research
